| Heading: |
Batten Disease: Cerliponase Alfa |
| Question ID: |
1815269 |
| UIN: |
HL8688 |
| House: |
Lords |
| Date tabled: |
2025-06-23 |
| Asking Member ID: |
4884 |
| Asking Member display name: |
Lord Botham
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Lord Botham
|
| Member interest: |
false |
| Question text: |
To ask His Majesty's Government what assessment they have made of the impact of ineligibility to receive cerliponase alfa for treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) on children born after January 2026; and what steps they are taking to |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-07-01 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
347 |
| Answering Member display name: |
Baroness Merron
|
| Answering Member handle: |
|
| Answering Member Twitter reference: |
Baroness Merron
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
In the absence of treatment with cerliponase alfa, clinical management of patients with neuronal ceroid lipofuscinosis type 2 (CLN2) focuses on symptom control, monitoring and preventing complications, and palliative care. The aim is to maintain function ... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |